Publication: 2292

Publication: 2292

Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405

DOI

URL

URL

Google Scholar

Citation:: J Clin Oncol vol 33 (suppl) abstr 3585

Meeting Instance:: ASCO 2015
Year:: 2015
Type:: Abstract
Sub type:: Poster General
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pub

Note:: This research was also supported by Bristol-Myers Squibb, Genentech, and Pfizer

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 4559

Program:: OGC
Primary Committee:: GI
Sec. Committees:

Pharmas:: Bristol-Myers Squibb, Genentech, and Pfizer
Grants:: U10CA180821, U10CA180882, CA31946

Corr. Author:
Authors:: Volker Heinemann Donna Niedzwiecki Rachel Pearline Heinz-Josef Lenz Federico Innocenti Howard S. Hochster Axel Grothey Richard M. Goldberg Robert J. Mayer Richard L. Schilsky Monica M. Bertagnolli Charles D. Blanke Alan P. Venook Sebastian Stinzing Bert H. O'Neil

Networks:: CA011, CA824, LAPS-IL057, LAPS-IN007, LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-OH007, OR013

Study: CALGB-80405
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: